Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02819440 · ClinicalTrials.gov registry record · Phase 2
PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction
A Phase 2 study of Healthy and Obese, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 141
- Enrollment target
- 1
- Study location
NCT02819440 is a Phase 2 study of Healthy and Obese that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 141 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02819440, a Phase 2 study of Healthy and Obese, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 141 participants
- Enrollment target
- 1
- Study location
Study Summary
Obesity and its adverse cardiometabolic consequences are major public health problems. Several features of obesity contribute to the associated cardiovascular risk and are potential targets for intervention. These include insulin resistance and beta cell dysfunction, reduced metabolic rate, and impaired aerobic capacity.The purpose of this study is to examine if the phosphodiesterase type 5A inhibitor tadalafil improves cardiometabolic health in individuals who are obese and insulin resistant.
Interventions
- DRUG Placebo
- DRUG Tadalafil
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2016-07 |
| Est. Completion | 2020-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02819440
The ClinicalTrials.gov registry entry for NCT02819440 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (78% lower). The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02819440 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT02819440 about?
NCT02819440 is a clinical study titled "PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction". Obesity and its adverse cardiometabolic consequences are major public health problems. Several features of obesity contribute to the associated cardiovascular risk and are potential targets for intervention. These include insulin resistance and beta cell dysfunction, reduced metabolic rate, and impa...
What is the current status of trial NCT02819440?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 141 participants. The study started on 2016-07. Estimated completion is 2020-06.
What conditions does trial NCT02819440 study?
This clinical trial studies the following conditions: Healthy, Obese.
What interventions are being tested in trial NCT02819440?
The interventions under investigation include: Placebo (DRUG), Tadalafil (DRUG).
Who is sponsoring clinical trial NCT02819440?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02819440 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Nasal Treatment for COVID-19
RECRUITING · Phase 2
-
Viral Mucosal Reprogramming
RECRUITING · Phase 2
-
Effects of an Antioxidant Supplement on Blood Vessel Health
RECRUITING · Phase 2
-
Atenolol for the Prevention of Osteoporosis (APO)
ACTIVE NOT RECRUITING · Phase 2
-
Effectiveness of Aquamin® in Mitigating Halitosis
ACTIVE NOT RECRUITING · Phase 2
-
Effects of Nitrite on Blood Vessel Dilation in Normal Volunteers
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.